Startup profile · funding coverage
Estuary Biotherapeutics funding, valuation and investors
Preclinical, locally delivered gene therapies for inherited kidney disease.
Keep track of Estuary Biotherapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A — committed financing announced; disbursement not specified
$93 million · October 16, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$103M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a · Newton, Massachusetts, United States
Investors in latest funding
Lead: RA Capital Management
Other: Deep Track Capital , Biogen New Ventures , UPMC Enterprises , Pivotal bioVenture Partners , National Kidney Foundation Innovation Fund , 4BIO Capital , GV , Unnamed ADPKD-connected family office
Overview
Estuary Biotherapeutics is developing kidney-directed AAV gene therapies for autosomal dominant polycystic kidney disease (ADPKD). Its October 16, 2026 launch disclosed $103M total committed financing, comprising $93M Series A and a prior $10M seed; this is not a single $103M new round.
Why Estuary Biotherapeutics is interesting
A large specialist-backed Series A commitment supports a kidney-delivery platform. The important investment milestones are clinical authorization, reproducible local delivery and human safety and activity—not preclinical disease-reversal claims alone.
Product & use cases
EST-201 delivers full-length PKD2 and targets clinical entry in 2027. EST-101 delivers a PC1-derived functional region for PKD1-associated disease and targets clinical entry in 2028. Programs are preclinical and investigational; human safety and efficacy are not established.
Funding history (newest first)
Series A — committed financing announced; disbursement not specified
2026-10-16 $93 million- RA Capital Management (lead)
- Deep Track Capital (participant)
- Biogen New Ventures (participant)
- UPMC Enterprises (participant)
- Pivotal bioVenture Partners (participant)
- National Kidney Foundation Innovation Fund (participant)
- 4BIO Capital (participant)
- GV (participant)
- Unnamed ADPKD-connected family office (participant)
Prior seed — disclosed at October 2026 launch; exact close date not stated
$10 millionInvestors in our directory
Funds linked from Estuary Biotherapeutics's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Its strategy targets the genetic biology of ADPKD through local gene delivery. Potential differentiation remains unproven clinically; genotype-specific programs have distinct development requirements.
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover Estuary Biotherapeutics's financing or category context.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.